Valeant Pharmaceuticals International, Inc.is a multinational specialty pharmaceutical company that develops manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics. First Manhattan Co added VRX to its portfolio by purchasing 56 company shares during the most recent quarter which is valued at $1,316.Breton Hill Capital Ltd. boosted its stake in VRX in the latest quarter, The investment management firm added 627 additional shares and now holds a total of 17,379 shares of Valeant Pharmaceuticals Intl Inc which is valued at $375,734. Analysts expect the company to announce earnings of $1.44 per share for the quarter. 11,379,497 shares exchanged hands, whereas the company’s average trading volume stands at 27,696,541 shares.
Advertisement
On the ratings front, VRX has been the subject of a number of recent research reports. The shares were acquired at an average price of $24.48 per share, with a total value of $4,944,960.00.
The share price of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) plunged -91.14% for the year. According to analysts minimum EPS for the current quarter is expected at $1.2 and can go high up to $1.77. The company had revenue of $2371.60 million for the quarter, compared to analysts expectations of $2337.60 million. The stock had closed at $22.24 on the previous day. During the same quarter in the previous year, the company posted $2.05 EPS. Valeant Pharmaceuticals Intl Inc (NYSE:VRX)’s distance from 20 day simple moving average is -3.99% whereas its distance from 50 day simple moving average is -6.47% along with -62.89% distance from 200 day simple moving average. Royal Bank Of Canada restated a “sector perform” rating and issued a C$33.00 price objective (down from C$58.00) on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, June 8th.
In terms of Buy/Sell recommendations, analysts have a consensus rating of 3 on the shares of Valeant Pharmaceuticals Intl Inc (NYSE:VRX). The Developed Markets segment consists of (i) sales in the US of pharmaceutical products, OTC products, and medical device products, as well as alliance and contract service revenues, in the areas of eye health, dermatology and podiatry, aesthetics and dentistry, (ii) sales in the USA of pharmaceutical products indicated for the treatment of neurological and other diseases, as well as alliance revenue from the licensing of various products it developed or acquired, and (iii) pharmaceutical products, OTC products, and medical device products sold in Canada, Australia, New Zealand, Western Europe and Japan. The Company operates through two segments: developed markets and emerging markets.
Advertisement
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.
